Abstract:Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that have an effect on public health. Clinical investigations and further exploration of these mechanisms could lead to innovative, effective, and personalized treatment strategies for individuals. It is important to screen biomarkers in previous studies to discover what is missing. Glucagon-like peptide-1′s role in insulin secretion and glucose control highlights its diagnostic and therapeutic potential. Glucose-dependent insulinotropic peptide's influence on postprandial satiety and weight management signifies its importance in understanding metabolic processes. Monocyte chemoattractant protein-1′s involvement in inflammation and insulin resistance underlines its value as a diagnostic marker. Insulin-like growth factor-binding protein-7's association with insulin sensitivity and kidney function presents it as a potential target for these diseases' management. In validating these biomarkers, it will be easier to reflect pathophysiological processes, and clinicians will be able to better assess disease severity, monitor disease progression, and tailor treatment strategies. The purpose of the study was to elucidate the significance of identifying novel biomarkers for type 2 diabetes mellitus and obesity, which can revolutionize early detection, risk assessment, and personalized treatment strategies. Standard literature searches of PubMed (MEDLINE), EMBASE, and Cochrane Library were conducted in the year 2023 to identify both original RCTs and recent systematic reviews that have explored the importance of identifying novel biomarkers for T2D and obesity. This search produced 1964 results, and then was reduced to randomized controlled trial and systematic reviews, producing 145 results and 44 results, respectively. Researchers have discovered potential associations between type 2 diabetes mellitus and obesity and the biomarkers glucagon-like peptide-1, glucose-dependent insulinotropic peptide, monocyte chemoattractant protein-1, and insulin-like growth factor-binding protein-7. Understanding the role of those biomarkers in disease pathogenesis offers hope for improving diagnostics, personalized treatment, and prevention strategies.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to identify and validate new biomarkers related to type 2 diabetes (T2D) and obesity in order to improve the early detection, risk assessment, and personalized treatment strategies for these metabolic diseases. Specifically, the paper focuses on the following biomarkers: 1. **GLP - 1 (Glucagon - like Peptide - 1)**: - **Function**: GLP - 1 is an incretin hormone secreted by intestinal L cells after food intake, and its main function is to regulate blood - glucose homeostasis and insulin secretion. - **Problem**: In patients with type 2 diabetes, the function of GLP - 1 is often impaired, leading to decreased insulin secretion and blood - glucose control disorders. In obese individuals, the secretion of GLP - 1 is also often dysregulated, resulting in impaired satiety signals. 2. **GIP (Glucose - Dependent Insulin - releasing Peptide)**: - **Function**: GIP is a hormone secreted by intestinal K cells after the intake of glucose and fatty acids, which stimulates insulin release and energy storage in adipose tissue. - **Problem**: In patients with type 2 diabetes, the level of GIP may be decreased or the β - cell response to GIP may be weakened. In obese individuals, the GIP level is elevated, promoting lipid deposition and inhibiting lipolysis. 3. **MCP - 1 (Monocyte Chemoattractant Protein - 1)**: - **Function**: MCP - 1 is a chemokine that recruits immune cells to the site of inflammation and is related to chronic inflammation. - **Problem**: In obese individuals, the level of MCP - 1 is elevated, leading to chronic inflammation and insulin resistance. In patients with type 2 diabetes, the elevation of MCP - 1 level is associated with an increased risk of the disease. 4. **IGFBP - 7 (Insulin - like Growth Factor - Binding Protein - 7)**: - **Function**: IGFBP - 7 regulates insulin - like growth factors (IGFs), affecting insulin sensitivity, adipocyte function, and glucose metabolism. - **Problem**: IGFBP - 7 is related to insulin resistance and metabolic syndrome, and especially plays an important role in diabetic kidney injury. By studying the roles of these biomarkers in the occurrence and development of diseases, the paper aims to provide new diagnostic tools and treatment targets, thereby improving the management of type 2 diabetes and obesity. Specific objectives include: - **Early Detection**: By identifying these biomarkers, the risk of type 2 diabetes and obesity can be detected earlier. - **Risk Assessment**: These biomarkers can help assess an individual's risk of getting sick, so that preventive measures can be taken. - **Personalized Treatment**: According to the expression of biomarkers, personalized treatment plans are formulated to improve the treatment effect. In general, through a systematic review and analysis of existing literature, this paper explores the roles of GLP - 1, GIP, MCP - 1, and IGFBP - 7 in type 2 diabetes and obesity, aiming to provide new perspectives and tools for clinicians and researchers to better manage and treat these metabolic diseases.

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity

The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus

The Emerging Role of Biomarkers in the Diagnosis of Gestational Diabetes Mellitus

Metagenomic Analysis of Duodenal Microbiota Reveals a Potential Biomarker of Dysbiosis in the Course of Obesity and Type 2 Diabetes: A Pilot Study

Biomarkers of insulin sensitivity/resistance

Metabolomic signature between diabetic and non-diabetic obese patients: A protocol for systematic review

A review of biomarkers in the context of type 1 diabetes: Biological sensing for enhanced glucose control

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin

The association of cardiometabolic, diet and lifestyle parameters with plasma glucagon-like peptide-1: An IMI DIRECT study

Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients—The Debate Is Still Open

IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention—Results from Randomized Controlled Trials

1252-P: Differences in Cardiometabolic and Immune Biomarkers between Novel Subphenotypes of Individuals at Elevated Risk for Type 2 Diabetes

Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Predictive Utility of Biochemical Markers for the Diagnosis and Prognosis of Gestational Diabetes Mellitus

Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process

Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists